Skip to main content
Fig. 4 | BMC Ophthalmology

Fig. 4

From: Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial

Fig. 4

Mean change in CRT from baseline to the last visit by baseline ischemia. CRT, central retinal thickness; IVR, intravitreal ranibizumab; In general, linear model with treatments in two groups and baseline CRT included, mean gains in CRT from baseline to week 52 were not statistically different between two groups in patients with ischemia (P = 0.7749) or without ischemia at baseline (P = 0.3901). Change in CRT from baseline to week 52 in patients with or without ischemia were normally distributed (all P > 0.05 in Shapiro-Wilk tests). Mean ± SD change in CRT from baseline to week 52 in patients with ischemia was − 272.0 ± 240.1 μm in IVR group, − 237.3 ± 212.3 μm in IVR + Laser group. Mean ± SD change in CRT at week 52 from baseline in patients without ischemia was − 285.6 ± 144.6 μm in IVR group and − 395.6 ± 245.0 μm in IVR + Laser group

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us